SCHEMBL5009833

SCHEMBL5009833

CCCC1CC(=O)N(CCCCC(N)=O)C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.40
BRD4 O60885 3/20 0.40
APEX1 P27695 1/20 0.39
BLM P54132 1/20 0.39
MEN1 O00255 2/20 0.37
CYP2C19 P33261 2/20 0.37
KMT2A Q03164 2/20 0.37
GBA1 P04062 1/20 0.35
ALDH1A1 P00352 1/20 0.34
PTGER4 P35408 3/20 0.33
PTGER3 P43115 3/20 0.33
PTGER2 P43116 3/20 0.33
ABHD16A O95870 1/20 0.33
GAA P10253 1/20 0.32
FAAH O00519 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
SOAT1 P35610 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563597 0.99 L3MBTL1 (0.39) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL15361830 0.96 BRD4 (0.41) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL15719198 0.93 L3MBTL1 (0.39) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL5009182 0.91 BRD4 (0.41) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL2336934 0.91 L3MBTL1 (0.40) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL5012989 0.89 PTGER4 (0.43) L3MBTL1BRD4MEN1CYP2C19KMT2A
SCHEMBL25637726 0.82 APEX1 (0.58) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL563437 0.82 APEX1 (0.58) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL16058256 0.82 L3MBTL1 (0.36) L3MBTL1BRD4APEX1BLMMEN1
SCHEMBL28216946 0.81 BRD4 (0.47) L3MBTL1BRD4MEN1CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7358276-B2 for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent UCB, S.A. (BE) 2008-04-15 US disclosed
US-20050171188-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2005-08-04 US disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171188-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 L3MBTL1 4332/4885BRD4 2140/4885APEX1 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.